Sequence information
Variant position: 1691 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1863 The length of the canonical sequence.
Location on the sequence:
KHHITLTNLITEETTHVVMK
T DAEFVCERTLKYFLGIAGGK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KHHITLTNLITEETTH-VVMKT DAEFVCERTLKYFLGIAGGK
Gorilla KHHITLTNLITEETTH-VVMKT DAEFVCERTLKYFLGIAGG
KHHISLTNLISEETTH-VIMKT DAEFVCERTLKYFLGIAGG
Rhesus macaque RYHIALTNLISEETTH-VVMKT DAEFVCERTLKYFLGIAGG
Chimpanzee KHHITLTNLITEETTH-VVMKT DAEFVCERTLKYFLGIAGG
Mouse KYRLTLTDAITEETTH-VIIKT DAEFVCERTLKYFLGIAGG
Rat KYRLALTDVITEETTH-VIIKT DAEFVCERTLKYFLGIAGG
Bovine KHHVTLTNLITEETTH-VIMKT DPEFVCERTLKYFLGIAGG
Caenorhabditis elegans D--------VNEHTTHLVMMNS EGRSISQKSTAYLYAIARK
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1863
Breast cancer type 1 susceptibility protein
Domain
1642 – 1736
BRCT 1
Alternative sequence
64 – 1863
Missing. In isoform 2.
Mutagenesis
1671 – 1671
K -> E. Impairs formation of a heterotetramer with ABRAXAS1.
Mutagenesis
1700 – 1700
T -> A. Strongly reduces affinity for a BRIP1 phosphopeptide.
Mutagenesis
1702 – 1702
K -> M. Abolishes interaction with BRIP1.
Literature citations
A high-throughput functional complementation assay for classification of BRCA1 missense variants.
Bouwman P.; van der Gulden H.; van der Heijden I.; Drost R.; Klijn C.N.; Prasetyanti P.; Pieterse M.; Wientjens E.; Seibler J.; Hogervorst F.B.; Jonkers J.;
Cancer Discov. 3:1142-1155(2013)
Cited for: CHARACTERIZATION OF VARIANTS BC PHE-4; THR-18; GLN-45; GLY-61; GLY-64; TYR-67; LYS-132; HIS-142; PHE-147; PRO-165; TRP-170; TYR-186; ILE-191; MET-231; VAL-245; VAL-246; LEU-271; PHE-668; ASN-695; LEU-798; TYR-810; LYS-826; GLN-841; HIS-856; ASN-1101; ASN-1140; GLY-1140; LYS-1214; LYS-1236; SER-1267; VAL-1282; SER-1297 DEL; ARG-1301; LYS-1346; ILE-1378; VAL-1400; PRO-1407; THR-1411; GLY-1443; GLY-1448; CYS-1486; MET-1534; PRO-1589; THR-1628; PRO-1651; PHE-1651; PHE-1655; ARG-1686; GLN-1686; VAL-1688 DEL; ILE-1691; TRP-1699; GLN-1699; GLU-1706; ALA-1706; GLU-1708; CYS-1718; ALA-1720; LYS-1735; ALA-1736; GLY-1739; VAL-1739; GLN-1746; THR-1753; PRO-1764; SER-1767; VAL-1770; CYS-1782; THR-1789; ASP-1794; ASP-1804; ARG-1812; ARG-1837 AND LEU-1862; VARIANTS CYS-105; CYS-866; ALA-1060; LYS-1250 AND ILE-1652;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.